Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare L Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Brian Dougherty; Maria Orr; Darren Hodgson; J Carl Barrett; Ursula Matulonis

doi:10.1016/s1470-2045(14)70228-1

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70228-1 ◽

2014 ◽

Vol 15 (8) ◽

pp. 852-861 ◽

Cited By ~ 793

Author(s):

Jonathan Ledermann ◽

Philipp Harter ◽

Charlie Gourley ◽

Michael Friedlander ◽

Ignace Vergote ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Retrospective Analysis ◽

Serous Ovarian Cancer ◽

Phase 2 ◽

Platinum Sensitive ◽

Phase 2 Trial

Download Full-text

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30376-x ◽

2016 ◽

Vol 17 (11) ◽

pp. 1579-1589 ◽

Cited By ~ 208

Author(s):

Jonathan A Ledermann ◽

Philipp Harter ◽

Charlie Gourley ◽

Michael Friedlander ◽

Ignace Vergote ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Serous Ovarian Cancer ◽

Phase 2 ◽

Double Blind ◽

Platinum Sensitive ◽

Phase 2 Trial

Download Full-text

Faculty Opinions recommendation of Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726731816.793527328 ◽

2017 ◽

Author(s):

Katherine Fuh

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Serous Ovarian Cancer ◽

Phase 2 ◽

Double Blind ◽

Platinum Sensitive ◽

Phase 2 Trial

Download Full-text

Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5535 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5535-5535 ◽

Cited By ~ 1

Author(s):

Jung-min Lee ◽

Joyce Liu ◽

Peter L. Choyke ◽

Osama Elbuluk ◽

Ismail B. Turkbey ◽

...

Keyword(s):

Ovarian Cancer ◽

Parp Inhibitor ◽

Phase 2 ◽

Platinum Sensitive ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and aBRCAmutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Cancer ◽

10.1002/cncr.29995 ◽

2016 ◽

Vol 122 (12) ◽

pp. 1844-1852 ◽

Cited By ~ 48

Author(s):

Ursula A. Matulonis ◽

Philipp Harter ◽

Charlie Gourley ◽

Michael Friedlander ◽

Ignace Vergote ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Maintenance Therapy ◽

Adenosine Diphosphate ◽

Inhibitor Therapy ◽

Serous Ovarian Cancer ◽

Platinum Sensitive ◽

Polymerase Inhibitor

Download Full-text

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.015 ◽

2015 ◽

Vol 137 ◽

pp. 8

Author(s):

U.A. Matulonis ◽

P. Harter ◽

C. Gourley ◽

M. Friedlander ◽

I.B. Vergote ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Maintenance Therapy ◽

Brca Mutation ◽

Parp Inhibitor ◽

Inhibitor Therapy ◽

Serous Ovarian Cancer ◽

Platinum Sensitive

Download Full-text

Health-Related Quality of Life (Hrqol) During Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Serous Ovarian Cancer (Psr Soc) and a Brca Mutation (Brcam)

Annals of Oncology ◽

10.1093/annonc/mdu338.11 ◽

2014 ◽

Vol 25 ◽

pp. iv308 ◽

Cited By ~ 2

Author(s):

J.A. Ledermann ◽

P. Harter ◽

C. Gourley ◽

M. Friedlander ◽

I.B. Vergote ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Maintenance Therapy ◽

Brca Mutation ◽

Serous Ovarian Cancer ◽

Health Related Quality ◽

Platinum Sensitive ◽

Related Quality ◽

Health Related

Download Full-text